Abstract
Developers of cell-based therapies intended for the treatment of cardiovascular indications must address a number of regulatory issues related to the manufacturing and delivery of living cell products to patients. This article highlights issues that must be considered regarding the cell and tissue source and ancillary materials, the development of a regulatory acceptable manufacturing process, the importance of product characterization as a measure of product quality and clinical site logistics for handling and storing living cell products. Finally, regulatory issues regarding the various delivery systems commonly used for delivery cells to cardiac tissues are touched upon.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
